A look at statin cost-effectiveness in view of the 2013 ACC/AHA cholesterol management guidelines

Current Atherosclerosis Reports

Volumn 16, Issue 9, 2014, Pages

  Deaño, Roderick C ^a   Pandya, Ankur ^b   Jones, Erica C ^a   Borden, William B ^c  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Cardiovascular disease; Cholesterol; Cost effectiveness; Guidelines; Risk

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASES; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; METABOLISM; PRACTICE GUIDELINE;

CARDIOVASCULAR DISEASES; CHOLESTEROL; COST-BENEFIT ANALYSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRACTICE GUIDELINES AS TOPIC;

EID: 84904535033     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-014-0438-9     Document Type: Review

References (32)

1. Stone NJ, Robinson J, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013. doi:10.1161/01.cir.0000437738.63853.7a. This is the main ACC/AHA guideline on treatment of blood cholesterol to reduce cardiovascular risk that details the groups that are recommended for statin therapy.
2. National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
3. Ioannidis JPA. More than a billion people taking statins? Potential implications of the new cardiovascular guidelines. JAMA. 2014;311(5):463-4.
4. Pencina MJ, Navar-Boggan AM, D'Agostino RB, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370(15):1422-31.
5. Weinstein MC, Stason W. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296:716-21. (Pubitemid 8066534)
6. Evans C, Tavakoli M, Crawford B. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manag Sci. 2004;7(1):43-9. (Pubitemid 39024064)
7. Braithwaite RS, Meltzer DO, King Jr JT, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4):349-56.
8. Prosser LA, Stinnett AA, Goldman PA, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med. 2000;132:769-79. (Pubitemid 30317791)
9. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility Analysis. Ann Intern Med. 2006;144:326-36. (Pubitemid 46768187)
10. Pletcher MJ, Lazar L, Bibbins-domingo K, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid lowering. Ann Intern Med. 2009;150:243-54.
11. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med. 2010;152:69-77.
12. Lazar LD, Pletcher MJ, Coxson PG, Bibbins-domingo K, Goldman L. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011;124(2):146-53. This article projected the cost-effectiveness of statin therapies for primary prevention using low-cost generic medications.
13. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-35. (Pubitemid 40471450)
14. Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Lindahl C, Tsai J. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437-46.
15. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-504. (Pubitemid 38477774)
16. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJM, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis. J Am Coll Cardiol. 2008;51(1):37-45.
17. Ganz DA, Kuntz KM, Jacobson GA, Avorn J. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med. 2000;132:833-5.
18. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Ann Intern Med. 1998;129(9):681-9. (Pubitemid 28507140)
19. Marcus FI, Friday K, Mccans J, et al. Age-related prognosis after acute myocardial infarction (the Multicenter Diltiazem Postinfarction Trial). Am J Cardiol. 1990;65:559-66. (Pubitemid 20091880)
20. Chan PS, Nallamothu BK, Gurm HS, Hayward RA, Vijan S. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation. 2007;115(18):2398-409. (Pubitemid 46717962)
21. Heart Protection Study Collaborative Group. Statin cost-effectiveness in the United States for people at different vascular risk levels. Circ Cardiovasc Qual Outcomes. 2009;2(2):65-72.
22. Mullins CD, Rattinger GB, Kuznik A, Koren MJ. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study. Clin Ther. 2008;30:2204-16.
23. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol. 2004;44(9):1772-9. (Pubitemid 39424074)
24. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-96. (Pubitemid 39140624)
25. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117-25.
26. Ramsey SD, Clarke LD, Roberts CS, Sullivan SD, Johnson SJ, Liu LZ. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes. Pharmacoeconomics. 2008;26(4):329-39. (Pubitemid 351457479)
27. Ohsfeldt RL, Gandhi SK, Smolen LJ, et al. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. J Med Econ. 2010;13(3):428-37.
28. Taylor F, Huffman M, Macedo A, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1, CD004816.
29. Mitchell AP, Simpson RJ. Statin cost effectiveness in primary prevention: a systematic review of the recent cost-effectiveness literature in the United States. BMC Res Notes. 2012;5(1):373.
30. Cutler DM, Rosen AB, Vijan S. The value of medical spending in the United States, 1960-2000. N Engl J Med. 2006;355(9):920-7. (Pubitemid 44315984)
31. D'Agostino RB, Ansell B, Mora S, Krumholz H. The guidelines battle on starting statins. N Engl J Med. 2014;371(17):1652-8.
32. Ting HH, Brito JP, Montori VM. Shared decision making: science and action. Circ Cardiovasc Qual Outcomes. 2014;7(2):323-7.